Forgot your password?

Forgot your username?

NEWS
Additional Validation Data Report for Antibe’s Ongoing Development of ATB-346
May 12 2015

Results of additional testing have been recently announced by Antibe Therapeutics pertaining to the progress of the developmental procedures being conducted by the company for their ATB-346 drug. These recent validation data show further proof that ATB-346 can be effective even if administered at a lower dosage. The frequency of taking it has also been[…]




Wafergen’s Smartchip Mydesign Genomic Technology to be Employed by Procter & Gamble
May 11 2015

Wafergen Biosystems and Procter & Gamble recently announced their industrial partnership that involves the latter utilizing the former’s specialized quantitative PCR System namely SmartChip MyDesign. Proctor & Gamble will make use of Wafergen’s product for researches involving Gene Extraction among many others. Procter & Gamble have been reported to look at other similar technologies but[…]




Cellular Biomedicine Group Joins Force With Huntsworth Health For KOL Advocacy On Clinical Research For Knee Osteoarthritis
May 11 2015

Cellular Biomedicine Group, Inc. (CBMG) has took on Hunstworth Health to put in order a team of medical experts for a global KOL advocacy campaign for CBMG’s Rejoin clinical trials. The clinical trials are for Rejoin which is a human adipose-derived mesenchymal progenitor cell (haMPC) developed to be a cure for Knee Osteoarthritis (KOA). Phase IIb[…]




Capnia Develop Cluster Headache Medicine with Partner Clinvest
May 11 2015

A recently announced Memorandum of Understanding (MOU) between Capnia, Inc. and Clinvest, a Banyan Group, Inc. division, has brought about the formation of the collaboration between the two parties to develop a cure for cluster headache with the use of the former’s proprietary nasal CO2 treatment technology. Capnia has been known as a leading company[…]




Partners & Sponsors